Neural Therapy

Local anesthetics as therapy before the Huneke brothers

A health technology assessment written by neural therapy physicians says procaine was synthesized in 1905 and that early reports of therapeutic use by Schleich and Spiess drew little response. It credits the surgeon René Leriche with drawing attention to injections at sympathetic nerve structures, including the stellate ganglion, from the 1920s. A scoping review by neural therapy authors adds that Spiess reported in 1906 a rapid reduction of inflammation after procaine injections and attributed it to an effect on the nervous system. Both accounts come from practitioners writing about their own field.

Ferdinand and Walter Huneke

The same assessment tells the origin story as follows. In 1925 Ferdinand Huneke, a general practitioner in Düsseldorf, gave his sister, who had migraine, a combination preparation intravenously. He had picked the version meant for intramuscular use, which contained procaine, and the migraine stopped abruptly. A repeat dose of the version without procaine did not have the same effect, which led him to conclude that procaine was responsible. He and his brother Walter, also a physician, then applied it at painful tissues, nerves, joints and ganglia, and in 1928 published an article titled 'Unbekannte Fernwirkungen der Lokalanästhesie' (unknown distant effects of local anesthesia). This account has not been checked against independent records.

In 1940, according to the same sources, Ferdinand Huneke injected a chronic osteomyelitis scar on a patient's lower leg and the shoulder pain he had previously failed to relieve ended at once. He named this the Sekundenphänomen and replaced the older idea of a focus with the 'nervous interference field'. The assessment says the term neural therapy was formulated in 1940, extending segmental therapy with interference field therapy.

Textbooks, societies and spread

The assessment dates the first textbook, by Dosch, to 1964. The Austrian medical society for the method gives 1971 as its founding date. A 2014 master's thesis from the Universidad Nacional de Colombia, based on minutes and interviews, describes the method reaching Latin America in the 1970s, splitting in the 1980s into a technical and a systemic current, entering universities in the 1990s and being formalized as a medical system from the 2000s. The thesis was read through its abstract only.

Names for the practice

The full German name is Neuraltherapie nach Huneke, and the Spanish term is terapia neural. Some sources use 'therapeutic local anesthesia' or 'diagnostic local anesthesia' for the same injections. The 2005 assessment calls the first label confusing, because practitioners hold that the anesthetic effect is incidental to the therapy and that painless conditions can also be treated. An Austrian rapid review notes that terms for these injections overlap and are hard to separate, and that definitions differ on whether only injection into the skin or also just beneath it counts.

Segment and interference field

Within the practice, local or segmental therapy injects at or near the affected area or the spinal segment that supplies it. Interference field therapy injects at a site, often a scar, tooth, tonsil or sinus, that practitioners describe as a chronic irritation source acting outside the segment. A 2022 review by neural therapy authors argues that this division is outdated and proposes the term 'neuromodulatory trigger'. It reports that the terms are used synonymously with the endorsement of the advisory board of the international federation of neural therapy societies.

Wheals, mesotherapy and the Sekundenphänomen

Quaddel therapy, the injection of local anesthetic into the skin to raise wheals, is described as one component of neural therapy. Mesotherapy also injects into the skin, but uses mixtures of other drugs and is a separate method. In the 2005 assessment, the Sekundenphänomen is the rapid disappearance of distant symptoms after injecting a suspected interference field. It applies only if the complaints stay fully absent for at least 20 hours (8 for the jaw and teeth), a practitioner criterion that has not been independently tested.

Levels of injection

A qualitative study describes three approaches. Local treatment places the anesthetic in or near affected structures such as myofascial trigger points. Segmental treatment uses sites supplied by the same spinal segment, for example skin wheals, muscles, joints and ganglia. Interference field treatment targets areas of suspected low-grade chronic inflammation in scars, fractures, teeth, sinuses or the intestines. The Austrian society adds intravascular administration and states that adding other drugs is a matter for the treating physician and is not part of what it teaches.

Assessment and sessions

The Austrian society states that a physician's history and physical examination are required, and describes test injections used to map segmental and wider disturbances and to look for interference fields. A 2024 trial describes palpating eight points at the upper neck, the Adler-Langer points, to detect interference fields. In the 2018 interview study, patients stayed two weeks in a hospital integrative medicine unit and received on average 1.3 neural therapy treatments alongside conventional and complementary therapies. Patients described numbness, warmth, dizziness, fatigue or relaxation during or after injections.

Training and practitioners

The Austrian society states that the method is a medical activity limited to licensed physicians, and that its curriculum comprises 137 teaching units over at least two years and ends in a society diploma. It says safety, documentation and quality control are taught within that curriculum. The 2005 assessment describes a Swiss society that is a daughter organization of an international physicians' society, and a part-time chair of neural therapy at the University of Bern. The sources reviewed describe these societies' own standards and do not compare training across countries.

Indications named by practitioners

The Austrian society lists functional disorders and pain syndromes. The 2005 assessment, written by society members, names migraine, neuralgias, acute and chronic musculoskeletal pain, trigger points, inflammatory and degenerative rheumatic disease, renal colic, chronic cystitis and prostatitis, circulatory disorders, Raynaud disease and complex regional pain syndrome. The interview study adds gastrointestinal and functional cardiovascular complaints. These are practitioner claims, not findings of controlled studies.

The founding principles recorded in the assessment go further, holding that any chronic illness can be caused by an interference field and that such an illness can be resolved only by switching off the field. The Austrian rapid review states that the concept of distant effects across the body has not been adequately demonstrated.

What the published literature addresses

A scoping review of 129 studies of low-dose local anesthetics given for therapeutic purposes found that 73% concerned chronic pain, 13% acute pain and 14% other conditions. Musculoskeletal or myofascial pain accounted for 39 studies and migraine or headache for 31. Lidocaine was the most common agent, followed by procaine. The scoping design maps what has been studied and does not weigh how reliable each study is.

Evidence review of wheal injections

In 2026 the Austrian institute for health technology assessment reviewed intradermal wheal injections of local anesthetics for adults with musculoskeletal pain (search December 2025). It used one systematic review of eight trials and four randomized trials of 43 to 80 participants, with follow-up of at most 16 weeks. About 80% of this evidence concerned mesotherapy, with only one trial of intradermal lidocaine, so it is indirect for neural therapy as a whole. All publications had a high risk of bias, and no certainty grading was done.

Results were mixed. Pooled data from five studies in the review favored mesotherapy for pain by a difference the report judged borderline for clinical relevance, while two trials found no significant difference at one month. The report concluded that effectiveness is not established by high-quality evidence, that no patient-relevant benefit has been shown, and that no current guideline it found recommends the technique. Other injection studies, including neural therapy studies without a control group or using combined injections, were excluded on design.

Controlled, uncontrolled and qualitative studies

A 2024 randomized trial in 104 German inpatients compared individualized neural therapy (48) with no treatment (56) and tested the Adler-Langer points. Raters, including experienced neural therapists, agreed poorly on which points were tender or rigid. Pressure pain thresholds at five of eight points changed after treatment but not in the control group, measured 30 minutes later. The authors called the setting artificial and the palpation unreliable as a diagnostic tool. This record was read in abstract only.

A Turkish before-and-after study of 70 people with supraspinatus tendinopathy, mostly treated with injections into the skin and trigger points over three sessions, reported lower pain and disability scores four weeks later. It had no control group and was retrospective, and its authors noted the small sample and lack of long-term results. The interview study of 22 inpatients reported pain relief and emotional release, and called for trials separating specific from non-specific effects.

Practitioner-authored reviews

The 2005 assessment pooled 44 case collections and 15 retrospective cohort studies, covering 3,812 people, in two indication areas. It reported improvement in 50% to 80% of patients in the cohorts and described the case reports as selected best cases. The 2023 scoping review rated about 48% of its studies as showing a positive effect and a further 36% a potentially positive one, with 8.5% showing none. Both reviews were written largely by neural therapy practitioners, and neither is an appraisal of bias.

Disagreement over the interference field

The Austrian society states that the interference field's effect as a neuromodulator is scientifically established. The Austrian rapid review states that the mechanism of wheal injections is not scientifically clarified and that efficacy is disputed. The 2022 review does not rely on new clinical data. It argues from neurophysiology that segment boundaries are not fixed, so that interference fields should be redefined as neuromodulatory triggers. These sources conflict, and this page does not resolve the dispute.

Authorship and independence

Several key sources come from within the field. The 2005 assessment was written by members of the Swiss and international neural therapy societies. Authors of the 2022 review and the 2023 scoping review work in neural therapy practice or teaching, and the 2022 review notes no competing interests despite this. The most critical source here, the Austrian rapid review, covers only one part of the practice and mostly mesotherapy trials. No independent, adequately blinded trial of full neural therapy, including interference field injection, was found in the sources read.

Reported adverse events

In the interview study, the main adverse event was pain at injection, followed by vertigo, hot flashes, tiredness, headache and exhaustion, mostly lasting minutes to hours and in some cases up to two days. Some patients reported nightmares, crying or reliving earlier traumatic events. In the wheal-injection review, trials reported hematoma, brief burning and local bleeding. One study of mesotherapy reported injection-site pain or an allergic reaction in seven of 40 participants.

The Austrian review notes single reports of serious complications after related skin injections, including infections, granulomas, necrosis and an epidural abscess with paralysis, and says rarer harms are not captured by small trials. It adds that adverse events may go unrecorded. The scoping review reported only transient mild reactions and no severe events in the studies it covered, but its authors practice the method.

Contraindications and precautions

The interview study lists allergy to local anesthetics, coagulopathy, anticoagulation and skin infection as contraindications. The Austrian review reports a German guideline's warning about organ injury, anaphylaxis, seizures and cardiac rhythm disturbance after injected local anesthetics, and its note that ester-type agents such as procaine are more allergenic than amide types such as lidocaine. The 2005 assessment disputes the higher allergy risk of procaine. The scoping review cites needle risks such as hematoma and pneumothorax and says injection into spinal fluid can impair vital functions.

Care boundaries

None of the sources reviewed shows that the practice can replace diagnosis or necessary treatment, and the Austrian review found no guideline recommending it. New or worsening pain, weakness, numbness, fever, a swollen or red injection site, breathing difficulty, chest symptoms or faintness after an injection call for prompt medical assessment, and an emergency service for severe symptoms. People can ask a practitioner about training, hygiene, allergy history and medicines before agreeing to injections.